Access restricted to higher education institution's students and staff
master's thesis
Prognostički značaj imunohistokemijskih markera u difuznom B velikostaničnom limfomu

Marta Trobonjača (2016)
Metadata
TitlePrognostički značaj imunohistokemijskih markera u difuznom B velikostaničnom limfomu
AuthorMarta Trobonjača
Mentor(s)Antica Duletić-Načinović (thesis advisor)
Abstract
DLBCL spada u skupinu NH limofma sa udjelom od oko 30 posto. Nastaje na bilo kojem stupnju diferencijacije limfocita B. Morofološki te prognostički čini heterogenu skupinu bolesti. Korištenjem metode osnovne grupe limfoma; germinativnog i ne germinativnog tipa (spada ABC i nedifinirana podgrupa GEP razlikujemo dvije DLBCL). Zbog oteţane uporabljivosti u svakodnevnoj praksi GEP je zamijenjen IHC metodom. Prognostički značaj za odreĎene markere je utvrĎen iako njihov značaj nije jedinstveno dokazan u svim studijama. Ne postojanje jedinstvenog konsenzusa oko imunohistokemijskih metoda bi mogao biti uzrokom takvih razlika, čime je potreba za stvaranjem jedinstvenog algoritma i jedinstvenog konsenzusa oko metoda rada nuţna. Radi laške uporabe i razlikovanje podgrupa DLBCL te time i odreĎivanja prognoze pacijenta stvoreni su tzv. imunohistokemijski algoritmi. Osnovnu terapiju pacijenta čini akronim R-CHOP koja označava terapiju ciklofosfamidom, doksorubicinom (hidroksidaunorubicin), vinkristinom (oncovin), prednizonom, rituksimabom. UvoĎenje rituksimaba (monoklonalno anti-CD20 protutijelo) pokazalo se uspješnim u liječenju pacijenta. Ipak, kod čak 40 posto pacijenata dolazi do relapsa bolesti. Time su napori u daljnjem istraţivanju markera i njihove ekspresije u DLBCL povećani te postoje brojne kliničke studije za nove lijekove čiji cilj su pojedini proteini koje sam tumor izraţava na svojoj površini. Svrstavanjem pojedinih tipova DLBCL unutar različitih prognostičkih grupa s obzirom na prognozu za pacijenta DLCBL, potrebno je radi odreĎivanja prognoze bolesti čime je omogućeno individualizirano i bolje liječenje pacijenta.
Keywordsdiffuse large B – cell lymphoma prognostic markers immunohistochemoistry prognostic factors
Committee MembersToni Valković (committee chairperson)
Srđan Novak (committee member)
Vera Vlahović-Palčevski (committee member)
GranterSveučilište u Rijeci
Medicinski fakultet
Lower level organizational unitsKatedra za internu medicinu
PlaceRijeka
StateCroatia
Scientific field, discipline, subdisciplineBIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Study programme typeuniversity
Study levelintegrated undergraduate and graduate
Study programmeMedicine
Academic title abbreviationdr. med.
Genremaster's thesis
Language Croatian
Defense date2016-07-15
Parallel abstract (English)
DLBCL belongs to the group of NH lymphomas representing the part of around 30 percent of all lymphomas. It occurs at any stage of differentiation of lymphocytes B. Concerning morphologic and prognostic characteristics it represents a heterogeneous group of diseases. By the usage of the GEP method is is possible to distinguish two main groups of lymphomas; germinative and non germinative type (belongs to ABC and group of unclassified subgroup of DLBCL). Due to the difficult applicability in daily practice GEP is replaced by IHC. Prognostic value of certain markers is established, although their importance is not uniquely proven in all studies. Such differences could be the consequence of the fact that no consensus is reached on the existence of a unique immunohistochemical method for the diagnosis. Therefore, the need for creation of a unique algorithm and unique consensus on the methods used for diagnosis is necessary. Immunohistochemical algorithms were created for easier handling with tissue material and to distinguish DLBCL subgroups as well as for higher success in determining the prognosis of patients. Primary therapy of patient is described as acronym R-CHOP and indicates therapy with cyclophosphamide, doxorubicin (Hydroxydaunorubicin), vincristine (Oncovin) prednisone and rituximab. Introduction of rituximab (anti-CD20 monoclonal antibody) has proven successful in the treatment of the patient. However, 40 percent of patients experienced relapse. Thus, research efforts to broaden the usage of markers and to explain their expression in DLBCL resulted in numerous clinical trials and search for new drugs which target certain proteins that tumor cells express on its surface. Sorting certain types of DLBCL within different prognostic groups is necessary to determine the prognosis of disease, enabling individualized and better treatment of patients.
Parallel keywords (Croatian)difuzni veliko B-stanični limfom prognostički markeri imunohistokemija prognostički čimbenici
Resource typetext
Access conditionAccess restricted to higher education institution's students and staff
Terms of usehttp://rightsstatements.org/vocab/InC/1.0/
URN:NBNhttps://urn.nsk.hr/urn:nbn:hr:184:439040
CommitterBosa Licul